He, W.Eriksson, M.Eliasson, E.Grassmann, F.Bäcklund, M.Gabrielson, M.Hammarström, M.Margolin, S.Thorén, L.Wengström, Y.Borgquist, S.Hall, P.Czene, K.2022-11-302022-11-302021-10-01He, W, Eriksson, M, Eliasson, E, Grassmann, F, Bäcklund, M, Gabrielson, M, Hammarström, M, Margolin, S, Thorén, L, Wengström, Y, Borgquist, S, Hall, P & Czene, K 2021, 'CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial', Annals of Oncology, vol. 32, no. 10, pp. 1286-1293. https://doi.org/10.1016/j.annonc.2021.07.0050923-7534ORCID: /0000-0003-1390-7528/work/99292874https://hdl.handle.net/2164/19658Funding Information: This work was supported by Märit and Hans Rausing's Initiative Against Breast Cancer (no grant number); the Kamprad Foundation [grant number: 20150052 ]; and Stockholm County Council [grant number: 4-2645/2015 ]; the Swedish Research Council [grant number 2018-02547 ]; the Swedish Cancer Society [grant number 19 0266 ]; and Swedish Research Council for Health, Working Life and Welfare (FORTE) [grant number 2016-00081 , 2018-00877 ]. WH is supported by Zhejiang University through ‘Hundred Talents Program’ (no grant number). The funding source had no role in study design, collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to approve publication of the finished manuscript.8133817engSDG 3 - Good Health and Well-beingbreast cancerCYP2D6 genotypemammographic densitytamoxifentreatment discontinuationR MedicineHematologyOncologyOtherSupplementary DataRJournal article10.1016/j.annonc.2021.07.005http://www.scopus.com/inward/record.url?scp=85112111245&partnerID=8YFLogxK3210